These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 24815795

  • 1. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB, PACES Study Group.
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [Abstract] [Full Text] [Related]

  • 2. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group.
    Ann Intern Med; 2008 Oct 21; 149(8):521-30. PubMed ID: 18936500
    [Abstract] [Full Text] [Related]

  • 3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.
    Chest; 2012 Dec 21; 142(6):1383-1390. PubMed ID: 22628490
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr 21; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.
    J Heart Lung Transplant; 2011 Dec 21; 30(12):1327-33. PubMed ID: 22055098
    [Abstract] [Full Text] [Related]

  • 6. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct 21; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 7. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.
    J Heart Lung Transplant; 2013 Sep 21; 32(9):889-96. PubMed ID: 23953817
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
    Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, Block LH.
    Chest; 2003 Apr 21; 123(4):1293-5. PubMed ID: 12684325
    [Abstract] [Full Text] [Related]

  • 9. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov 04; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 11. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD, Jansa P, Teal S, Dombi T, Zhou D.
    BMC Cardiovasc Disord; 2017 Sep 06; 17(1):239. PubMed ID: 28874133
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar 06; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
    Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ, SUPER-2 Study Group.
    Chest; 2011 Nov 06; 140(5):1274-1283. PubMed ID: 21546436
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2012 Feb 06; 31(2):150-8. PubMed ID: 22138355
    [Abstract] [Full Text] [Related]

  • 15. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA.
    Pulm Pharmacol Ther; 2008 Oct 06; 21(5):824-32. PubMed ID: 18657627
    [Abstract] [Full Text] [Related]

  • 16. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
    Lichtblau M, Harzheim D, Ehlken N, Marra A, Pinado FP, Grünig E, Egenlauf B.
    Lung; 2015 Feb 06; 193(1):105-12. PubMed ID: 25318865
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

  • 18. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar 22; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C, Escribano Subias P, Tello de Meneses R, Delgado Jiménez JF, Sadia Pérez D, Velázquez Martín MT, Gómez Sánchez MA, Sáenz de la Calzada C.
    Rev Esp Cardiol; 2004 Oct 22; 57(10):946-51. PubMed ID: 15469792
    [Abstract] [Full Text] [Related]

  • 20. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
    Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD, STARTS-2 Investigators.
    Circulation; 2014 May 13; 129(19):1914-23. PubMed ID: 24637559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.